Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2014

View Archived Issues

Evidence suggests the utility of lncRNAs for preventing cardiac hypertrophy

AAV-mediated antibody gene delivey protects against malaria

Celon's PI3Kdelta inhibitor shows high potency and selectivity in vivo

Eisai and Kyorin enter into agreement for compound library use

EMD Serono and Accelerated Cure Project partner to optimize treatment for MS

Altor BioScience and Shenzhen Beike Biotechnology enter into license agreement for ALT-803

MabVax Therapeutics partners with MSK and Juno Therapeutics

Seattle Genetics and Genmab enter into new antibody-drug conjugate collaboration

Flex Pharma raises funds to support clinical candidates

Shionogi presents results for S-649266 for the treatment Gram-negative bacteria

Enrollment open in pivotal study of MGN-1703 for metastatic colorectal carcinoma

DECIDE trial results demonstrate positive benefits for DAC HYP

Charleston Laboratories updates progress of early-stage programs

Further funds for Ebola drug development and containment

Recent FDA orphan drug designations

New PI3K and mTOR inhibitors disclosed by Calitor Sciences and HEC Pharm

Pfizer synthesizes novel PDE4 inhibitors

Allergen divulges novel S1P1 receptor ligands

Novartis prepares new NEP inhibitors for hypertension and heart failure

FDA approves Pleximmune to predict transplant rejection in children

Sangamo plans IND filing next year for use of ZFN-mediated IVPRP in hemophilia B

Oxygen Biotherapeutics stops phase IIb trial of Oxycyte for traumatic brain injury

Phase II trial of myostatin-targeted MAb LY-2495655 meets primary objective

Merck Serono discontinues development of tecemotide as a monotherapy in NSCLC

Sprint Bioscience's VPS34 inhibitors evaluated as an antitumor strategy

FDA approves Xtandi for metastatic castration-resistant prostate cancer

ViaCyte receives accelerated development pathway grant for VC-01

FDA approves HyQvia for primary immunodeficiency

FDA advisory committee recommends approval of Natpara for hypoparathyroidism